Equillium
Joel is the Chief Development Officer at Equillium. He has more than 25 years of experience advancing therapeutics for a range of critical diseases. Prior to joining Equillium, Joel led development operations in the VP role for several other leading pharmaceutical and biotechnology companies including at Cytokinetics, Raptor Pharmaceuticals (acquired by Horizon Pharma) and Jazz Pharmaceuticals. Over the course of his career, Joel has directed clinical operations, clinical contracts and outsourcing, biostatistics and data management, and also has orchestrated due diligence, corporate acquisitions and corporate integrations. Earlier in his career, Joel served in senior roles at ICON Clinical Research, leading strategic business development and regional operations. Additionally, he has held positions in clinical research, operations and development at Anergen, Genentech and Procter & Gamble Pharmaceuticals. Joel received his Bachelor of Science in Biology from Albright College.
This person is not in any offices
Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients with severe autoimmune and inflammatory diseases who continue to suffer with high unmet medical needs.